ABOUT CYTIVA
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
PRODUCT VIDEOS
FEATURED PRODUCTS
-
Gene therapy holds promise for treating genetic diseases, but the path from concept to product is complex. Learn how to navigate each step of the viral vector workflow with greater speed and confidence.
-
Explore media solutions for viral vector production that support HEK293 and insect cells, with custom development, analytical testing, and scalable preparation tools to optimize performance.
-
“Services” and “support.” What do those words mean in the life science manufacturing industry? The truth is, they’re quite subjective—and relative to each company. Here’s how we define services and support at Cytiva.
-
Learn about a scalable, single-use platform with built-in automation and regulatory compliance that enables standardized manufacturing workflows for mRNA-LNP drug product production.
-
The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of lipid nanoparticles (LNPs) under cGMP conditions. Designed for efficient changeover and robust manufacturing processes, the system enables operational flexibility and standardized manufacturing of genomic medicines.
-
Discover a one-stop-shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications. Explore end-to-end biopharma services and systems.
-
Learn about coated magnetic particles that easily isolate and extract mRNA from a variety of sources and enable you to perform RT-PCR cDNA library construction, affinity purification, and more.
-
Synthesize oligonucleotides at scales of 10–100 mmol for early to mid-phase clinical trials or for diagnostic kits.
-
Looking for a user-friendly and compact oligonucleotide synthesizer with a large scale range? Discover a pilot-scale system that will take your drug through clinical development.
-
Explore systems for automated oligonucleotide synthesis, offered at a range of scales to support easy process development, optimization, scale up and transfer. Find the system that matches your needs.
-
Discover the platform for oligonucleotide development and scale-up that is the result of 30 years of collaboration with leading oligonucleotide pharma. Explore this solution's benefits, specifications, and more.
-
OligoProcess covers a range of 10 to 1800 mmol and is suitable for quantities required in clinical phases and commercial production.
-
By combining disruptive technology platforms with unparalleled genomic medicine development expertise, we're positioned to accelerate the development of LNP formulations and drug products.
-
Explore how consistent mixing, low-volume workflows, and scale-ready design help maintain LNP quality from discovery through clinical development—reducing risk and preserving data continuity.
-
With NxGen™ technology on the NanoAssemblr® Blaze™, important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.
-
The GenVoy-ILM T Cell Kit for mRNA is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr Spark instrument and cartridges.
-
GenVoy-ILM is a pre-optimized lipid mixture designed to encapsulate RNA – mRNA, gRNA, siRNA, miRNA, tRNA – in LNP.
-
The NanoAssemblr® Spark™ is ideal for nanomedicine formulation discovery and screening at microliter scales.
-
The system supports a robust and easily scalable oligonucleotide synthesis process and transfer to larger oligonucleotide synthesizers with high yield and quality.
-
The ÄKTA oligosynt™ oligonucleotide synthesizer is a compact, fully automated oligonucleotide synthesizer built for research and process development laboratories. The system supports a robust and easily scalable oligonucleotide synthesis process and transfer to larger oligonucleotide synthesizers with high yield and quality.
WEBINARS AND PODCASTS
APPLICATION NOTES
- TFF Cassettes With 100 kDa Membranes For RNA And LNP Applications
- Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges
- Coated Magnetic Particles For RNA Preparation
- Compact Oligonucleotide Synthesizer
- Oligonucleotide Synthesizers That Take You From Start To Finish
- Accelerate Your Oligonucleotide Development And Scale-Up Goals
- Understanding The Microfluidic Platforms For Scaling Nanoparticle Production
- Biacore™ SPR Systems For Titer Analysis Of Adeno-Associated Virus
- Low-Volume Production For Screening High-Value Nanoparticle Materials
- ÄKTA oligosynt™ Oligonucleotide Synthesizer
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Lipid nanoparticles enable precise, non-viral gene editing in T cells to achieve high HDR efficiency and viability in scalable workflows. Explore how this approach overcomes viral vector limitations.
-
Get a clear view of oligonucleotide development from synthesis to purification and filtration with practical insights to help you streamline workflows and stay ahead in the fight against disease.
-
Explore how lipid nanoparticles are revolutionizing cell therapy workflows to enable the precise delivery of mRNA and gene editing tools for next-generation treatments like CAR T and HSC therapies.
-
Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.
-
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
Discover how self-replicating RNA (srRNA) can revolutionize vaccine development with sustained protein expression, lower doses, and fewer side effects to advance next-gen RNA therapeutics.
-
The market for oligonucleotide therapeutics is expanding, and the pipeline is diverse. Gain insight into how you can fast-track your molecule's development with verified synthesizers, columns, and scientific support and expertise.
-
Learn about flexible control software that has revolutionized the way method creation, evaluation, and process optimizations for scale-up are completed.
-
Explore five key areas in oligonucleotide chemistry where improvements will have a huge influence on your synthesis quality.
-
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.